Quarterly ResultMay 15, 2026, 08:17 AM
60 Degrees Pharma Q1 Net Loss $(2.09)M; Going Concern Doubt Raised
AI Summary
60 Degrees Pharmaceuticals reported an increased net loss of $(2.09) million for the first quarter of 2026, compared to $(1.88) million in the prior year, with net revenue significantly declining to $76,377. The company's management raised substantial doubt about its ability to continue as a going concern due to accumulated losses and insufficient revenues. Despite this, cash and cash equivalents improved to $3.34 million, largely due to $3.37 million in net proceeds from an At-The-Market (ATM) offering during the quarter.
Key Highlights
- Raised substantial doubt about ability to continue as a going concern.
- Net loss attributed to 60P increased to $(2,089,214) for Q1 2026.
- Net revenue decreased to $76,377 in Q1 2026 from $183,011 in Q1 2025.
- Net cash used in operating activities increased to $(2,741,559) in Q1 2026.
- Cash and cash equivalents rose to $3,337,760 as of March 31, 2026.
- Received $3,369,752 in net proceeds from an ATM Offering in Q1 2026.
- Basic and diluted net loss per common share was $(1.28) for Q1 2026.
- Total Shareholders' Equity increased to $4,744,479 as of March 31, 2026.
Price Impact
More from SXTP